Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Trappe RU, et al. Among authors: hauser ia. J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19. J Clin Oncol. 2017. PMID: 27992268 Clinical Trial.
Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.
Trappe R, Hinrichs C, Appel U, Babel N, Reinke P, Neumayer HH, Budde K, Dreyling M, Dührsen U, Kliem V, Schüttrumpf S, Hauser IA, Mergenthaler HG, Schlattmann P, Anagnostopoulos I, Doerken B, Riess H. Trappe R, et al. Among authors: hauser ia. Am J Transplant. 2009 Oct;9(10):2331-7. doi: 10.1111/j.1600-6143.2009.02772.x. Epub 2009 Aug 6. Am J Transplant. 2009. PMID: 19663889 Free article.
Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU. Zimmermann H, et al. Among authors: hauser ia. Transplantation. 2012 Mar 15;93(5):543-50. doi: 10.1097/TP.0b013e318242162d. Transplantation. 2012. PMID: 22234349
Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wüthrich RP, Scheidl S, May C, Paulus EM, Mühlfeld A, Wolters HH, Pressmar K, Stahl R, Witzke O; ZEUS Study Investigators. Budde K, et al. Am J Transplant. 2012 Jun;12(6):1528-40. doi: 10.1111/j.1600-6143.2012.03994.x. Epub 2012 Mar 5. Am J Transplant. 2012. PMID: 22642473 Free article. Clinical Trial.
[Cytomegalovirus after renal transplantation - diagnosis, prevention and treatment].
Kliem V, Sester M, Nitschke M, Tönshoff B, Budde K, Hauser IA, Schmitt M, Höcker B, Witzke O. Kliem V, et al. Among authors: hauser ia. Dtsch Med Wochenschr. 2015 Apr;140(8):612-5. doi: 10.1055/s-0041-100777. Epub 2015 Apr 16. Dtsch Med Wochenschr. 2015. PMID: 25945912 German. No abstract available.
Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
Budde K, Zeier M, Witzke O, Arns W, Lehner F, Guba M, Jacobi J, Kliem V, Reinke P, Hauser IA, Vogt B, Stahl R, Rath T, Duerr M, Paulus EM, May C, Porstner M, Sommerer C; HERAKLES Study Group. Budde K, et al. Among authors: hauser ia. Nephrol Dial Transplant. 2017 Jun 1;32(6):1060-1070. doi: 10.1093/ndt/gfx075. Nephrol Dial Transplant. 2017. PMID: 28605781 Clinical Trial.
Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, Ackermann D, Guba M, Jacobi J, Hauser IA, Stahl R, Reinke P, Rath T, Veit J, Mehrabi A, Porstner M, Budde K; HERAKLES Study Group. Sommerer C, et al. Among authors: hauser ia. Am J Transplant. 2018 Dec;18(12):2965-2976. doi: 10.1111/ajt.14897. Epub 2018 Jun 3. Am J Transplant. 2018. PMID: 29722128 Free article. Clinical Trial.
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU. Zimmermann H, et al. Among authors: hauser ia. Transplantation. 2018 Nov;102(11):1914-1923. doi: 10.1097/TP.0000000000002269. Transplantation. 2018. PMID: 29757894
143 results